Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11905)
All Articles published online
|
Publishing Process of This Article
|
Apr 14, 2018 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, Nishimura A, Umegaki E. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol 2018; 24(14): 1550-1561 [PMID: 29662293 DOI: 10.3748/wjg.v24.i14.1550] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i14/1550.htm |
| Number | Citing Articles |
| 1 |
Wen-Tao Xu, Xiang-Bo Xu, Tian-Shu Ren, Xing-Shun Qi. Vonoprazan for treatment of gastroesophageal reflux disease: Research advances. World Chinese Journal of Digestology 2021; 29(21): 1248 doi: 10.11569/wcjd.v29.i21.1248
|
| 2 |
Yousef Abdel‐Aziz, David C. Metz, Colin W. Howden. Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders. Alimentary Pharmacology & Therapeutics 2021; 53(7): 794 doi: 10.1111/apt.16295
|
| 3 |
Richard H. Hunt, Carmelo Scarpignato. Potent Acid Suppression with PPIs and P-CABs: What’s New?. Current Treatment Options in Gastroenterology 2018; 16(4): 570 doi: 10.1007/s11938-018-0206-y
|
| 4 |
Carmelo Scarpignato, Michio Hongo, Justin C. Y. Wu, Christian Lottrup, Adriana Lazarescu, Ellen Stein, Richard H. Hunt. Pharmacologic treatment of GERD: Where we are now, and where are we going?. Annals of the New York Academy of Sciences 2020; 1482(1): 193 doi: 10.1111/nyas.14473
|
| 5 |
Daniel Martin Simadibrata, Ari Fahrial Syam, Yeong Yeh Lee. A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2022; 37(12): 2217 doi: 10.1111/jgh.16017
|
| 6 |
Daphne Ang, Seok Hwee Koo, Yiong Huak Chan, Thean Yen Tan, Gaik Hong Soon, Chin Kimg Tan, Kenneth Weicong Lin, Jaydeesh‐Khanna Krishnasamy‐Balasubramanian, Yu Jun Wong, Rahul Kumar, Rajesh R, Yiyuan Tan, Peng‐Lan Jeannie Ong, Yi‐Lyn Jessica Tan, James Weiquan Li, Andrew Boon‐Eu Kwek, Tiing Leong Ang. Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2022; 56(3): 436 doi: 10.1111/apt.17070
|
| 7 |
Qianjun Zhuang, Songfeng Chen, Xuyu Zhou, Xingyu Jia, Mengyu Zhang, Niandi Tan, Fangfei Chen, Zhanye Zhang, Junnan Hu, Yinglian Xiao. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis. American Journal of Gastroenterology 2024; doi: 10.14309/ajg.0000000000002714
|
| 8 |
Vincenzo Savarino, Elisa Marabotto, Patrizia Zentilin, Maria Giulia Demarzo, Nicola de Bortoli, Edoardo Savarino. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Design, Development and Therapy 2021; : 1609 doi: 10.2147/DDDT.S306371
|
| 9 |
Yuan Cheng, Jiali Liu, Xiang Tan, Yi Dai, Chune Xie, Xiaohong Li, Qiongqiong Lu, Fushun Kou, Hui Jiang, Junxiang Li. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences 2021; 66(1): 19 doi: 10.1007/s10620-020-06141-5
|
| 10 |
Tadayuki Oshima, Hiroto Miwa. How Does Vonoprazan Affect the Treatment of Erosive Esophagitis?. Digestive Diseases and Sciences 2021; 66(2): 642 doi: 10.1007/s10620-020-06387-z
|
| 11 |
Katsuhiko Iwakiri, Yasuhiro Fujiwara, Noriaki Manabe, Eikichi Ihara, Shiko Kuribayashi, Junichi Akiyama, Takashi Kondo, Hiroshi Yamashita, Norihisa Ishimura, Yuichi Kitasako, Katsunori Iijima, Tomoyuki Koike, Nobuo Omura, Tsutomu Nomura, Osamu Kawamura, Shuichi Ohara, Soji Ozawa, Yoshikazu Kinoshita, Satoshi Mochida, Nobuyuki Enomoto, Tooru Shimosegawa, Kazuhiko Koike. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. Journal of Gastroenterology 2022; 57(4): 267 doi: 10.1007/s00535-022-01861-z
|
| 12 |
M.A. Valdovinos Díaz, M. Amieva-Balmori, R. Carmona-Sánchez, E. Coss-Adame, O. Gómez-Escudero, M. González-Martínez, F. Huerta-Iga, E. Morel-Cerda, J.M. Remes-Troche, J.L. Tamayo-de la Cuesta, G. Torres-Villalobos, L.R. Valdovinos-García, G. Vázquez-Elizondo, A.S. Villar-Chávez, J.A. Arenas-Martínez. Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología. Revista de Gastroenterología de México (English Edition) 2024; 89(1): 121 doi: 10.1016/j.rgmxen.2023.12.002
|
| 13 |
Shu-Wei Liang, Ming-Wun Wong, Chih-Hsun Yi, Tso-Tsai Liu, Wei-Yi Lei, Jui-Sheng Hung, Lin Lin, BenjaminD Rogers, Chien-Lin Chen. Current advances in the diagnosis and management of gastroesophageal reflux disease. Tzu Chi Medical Journal 2022; 34(4): 402 doi: 10.4103/tcmj.tcmj_323_21
|
| 14 |
Ronnie Fass, Michael Vaezi, Prateek Sharma, Rena Yadlapati, Barbara Hunt, Tom Harris, Neila Smith, Eckhard Leifke, David Armstrong. Randomised clinical trial: Efficacy and safety of on‐demand vonoprazan versus placebo for non‐erosive reflux disease. Alimentary Pharmacology & Therapeutics 2023; 58(10): 1016 doi: 10.1111/apt.17728
|
| 15 |
Satoshi Shinozaki, Hiroyuki Osawa, Yasutoshi Kobayashi, Hirotsugu Sakamoto, Yoshikazu Hayashi, Yoshimasa Miura, Alan Kawarai Lefor, Hironori Yamamoto. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan. Scandinavian Journal of Gastroenterology 2018; 53(8): 897 doi: 10.1080/00365521.2018.1486883
|
| 16 |
Yuta Yokoya, Ataru Igarashi, Akihito Uda, Hisato Deguchi, Toshihisa Takeuchi, Kazuhide Higuchi. Cost-utility analysis of a ‘vonoprazan-first’ strategy versus ‘esomeprazole- or rabeprazole-first’ strategy in GERD. Journal of Gastroenterology 2019; 54(12): 1083 doi: 10.1007/s00535-019-01609-2
|
| 17 |
Carmelo Scarpignato, Richard H. Hunt. Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. Current Treatment Options in Gastroenterology 2021; 19(1): 94 doi: 10.1007/s11938-020-00330-x
|
| 18 |
Wentao Xu, Zhaohui Bai, Yiyang Shang, Jing Wang, Yujun Wong, Xingshun Qi. Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis. Therapeutic Advances in Gastroenterology 2023; 16: 175628482311678 doi: 10.1177/17562848231167858
|
| 19 |
Ronnie Fass, Guy E. Boeckxstaens, Hashem El-Serag, Rachel Rosen, Daniel Sifrim, Michael F. Vaezi. Gastro-oesophageal reflux disease. Nature Reviews Disease Primers 2021; 7(1) doi: 10.1038/s41572-021-00287-w
|
| 20 |
Hiroto Miwa, Akiko Shiotani, Masayoshi Takeda, Masahiro Eda, Toshiaki Kato, Toshitaka Yajima. Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease. Journal of Clinical Gastroenterology 2023; 57(4): 370 doi: 10.1097/MCG.0000000000001685
|
| 21 |
Dongke Wang, Dan Zhou, Xinghuang Liu, Zhiyue Xu, Tao Bai, Xiaohua Hou. Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms. Trials 2023; 24(1) doi: 10.1186/s13063-023-07760-9
|
| 22 |
Mengyu Zhang, Yinglian Xiao, Minhu Chen. The role of vonoprazan in patients with erosive esophagitis. Therapeutic Advances in Gastroenterology 2022; 15: 175628482211226 doi: 10.1177/17562848221122623
|
| 23 |
Chun-Yan Niu, Xiao-Chun Luo. Application of potassium competitive acid blockers in acid-related diseases. World Chinese Journal of Digestology 2021; 29(8): 383 doi: 10.11569/wcjd.v29.i8.383
|
| 24 |
Jiten P. Kothadia, Colin W. Howden. Potassium-Competitive Acid Blockers for the Treatment of Gastroesophageal Reflux Disease. Foregut: The Journal of the American Foregut Society 2024; 4(1): 7 doi: 10.1177/26345161231181357
|
| 25 |
M.A. Valdovinos-Diaz, M. Amieva-Balmori, R. Carmona-Sánchez, E. Coss-Adame, O. Gómez-Escudero, M. González-Martínez, F. Huerta-Iga, E. Morel-Cerda, J.M. Remes-Troche, J.L. Tamayo-de la Cuesta, G. Torres-Villalobos, L.R. Valdovinos-García, G. Vázquez-Elizondo, A.S. Villar-Chávez, J.S. Arenas-Martínez. Recomendaciones de buena práctica clínica en el diagnóstico y tratamiento de la enfermedad por reflujo gastroesofágico. Revisión por expertos de la Asociación Mexicana de Gastroenterología. Revista de Gastroenterología de México 2024; 89(1): 121 doi: 10.1016/j.rgmx.2023.12.002
|
| 26 |
Vincenzo Savarino, Elisa Marabotto, Patrizia Zentilin, Nicola De Bortoli, Pierfrancesco Visaggi, Manuele Furnari, Giorgia Bodini, Edoardo Giannini, Edoardo Savarino. How safe are heartburn medications and who should use them?. Expert Opinion on Drug Safety 2023; 22(8): 643 doi: 10.1080/14740338.2023.2238592
|
| 27 |
Yasuki Habu, Ryuhei Hamasaki, Motonobu Maruo, Tatsuya Nakagawa, Yuki Aono, Daisaku Hachimine. Treatment strategies for reflux esophagitis including a potassium‐competitive acid blocker: A cost‐effectiveness analysis in Japan. Journal of General and Family Medicine 2021; 22(5): 237 doi: 10.1002/jgf2.429
|
| 28 |
Xinyan Chen, Tao Chen, Yunzhe Huang, Minhui Wang, Yaqin Wang, Ping Wu, Xiaocui Xia, Pengfei Du, Jianbang Wu, Jie Shen, Yuanwei Jia. LC–MS/MS method for quick detection of vonoprazan fumarate in human plasma: Development, validation and its application to a bioequivalence study. Biomedical Chromatography 2024; doi: 10.1002/bmc.5860
|
| 29 |
Carmelo Scarpignato, Richard H. Hunt. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology 2019; 35(4): 344 doi: 10.1097/MOG.0000000000000543
|
| 30 |
Mun Young Cho, Yu Kyung Cho. Role of Potassium-competitive Acid Blockers in the Treatment of Gastric Acid-related Disorders. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(3): 167 doi: 10.7704/kjhugr.2023.0043
|
| 31 |
Hideki Mori, Hidekazu Suzuki. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. Journal of Neurogastroenterology and Motility 2019; 25(1): 6 doi: 10.5056/jnm18139
|
| 32 |
Monthira Maneerattanaporn, Rapat Pittayanon, Tanisa Patcharatrakul, Chalermrat Bunchorntavakul, Siam Sirinthornpanya, Panyavee Pitisuttithum, Asawin Sudcharoen, Uayporn Kaosombatwattana, Kawin Tangvoraphongchai, Reawika Chaikomin, Kamin Harinwan, Karjpong Techathuvanan, Sawangpong Jandee, Phuripong Kijdamrongthum, Anupong Tangaroonsanti, Kulthep Rattanakovit, Sakkarin Chirapongsathorn, Sutep Gonlachanvit, Surapol Surangsrirat, Duangporn Werawatganon, Kitti Chunlertrith, Varocha Mahachai, Somchai Leelakusolvong, Wanich Piyanirun. Thailand guideline 2020 for medical management of gastroesophageal reflux disease. Journal of Gastroenterology and Hepatology 2022; 37(4): 632 doi: 10.1111/jgh.15758
|
| 33 |
Daniel M Simadibrata, Elvira Lesmana, Muhammad I A Pratama, Adrianus J Sugiharta, Afiah S Winarizal, Yeong Y Lee, Ari F Syam. A systematic review with meta‐analysis: Efficacy and safety of potassium‐competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis. JGH Open 2024; 8(3) doi: 10.1002/jgh3.13053
|
| 34 |
Wattana Leowattana, Tawithep Leowattana. Potassium-competitive acid blockers and gastroesophageal reflux disease. World Journal of Gastroenterology 2022; 28(28): 3608-3619 doi: 10.3748/wjg.v28.i28.3608
|
| 35 |
Alexandra Selby, Mark Malamood. Diagnosis and Treatment of Refractory GERD. Current Treatment Options in Gastroenterology 2023; 21(3): 320 doi: 10.1007/s11938-023-00432-2
|
| 36 |
Hideharu Okanobu, Tomohiko Kohno, Kazuki Boda, Hidenori Ochi, Yoshinari Furukawa. Long-Term Clinical Course after Successful Initial Treatment in Patients with Mild Erosive Esophagitis: A Prospective Follow-Up Study. Digestion 2023; 104(4): 283 doi: 10.1159/000528690
|
| 37 |
Junichi Akiyama, Junko Sumida, Kenichiro Nakagawa, Atsushi Masamune, Navapan Issariyakulkarn, Tanisa Patcharatrakul, Katerina Shetler, Shiko Kuribayashi, Toshio Uraoka, George Triadafilopoulos. New developments in esophageal function testing and esophageal manifestations of connective tissue disorders. Annals of the New York Academy of Sciences 2020; 1481(1): 170 doi: 10.1111/nyas.14424
|
| 38 |
Tomohide Tanabe, Shintaro Hoshino, Noriyuki Kawami, Yoshimasa Hoshikawa, Yuriko Hanada, Nana Takenouchi, Osamu Goto, Mitsuru Kaise, Katsuhiko Iwakiri. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Esophagus 2019; 16(4): 377 doi: 10.1007/s10388-019-00676-x
|
| 39 |
Vincenzo Savarino, Luca Antonioli, Matteo Fornai, Elisa Marabotto, Maria Giulia Demarzo, Fabiana Zingone, Matteo Ghisa, Brigida Barberio, Patrizia Zentilin, Mentore Ribolsi, Edoardo Savarino. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Review of Gastroenterology & Hepatology 2022; 16(5): 401 doi: 10.1080/17474124.2021.1984878
|
| 40 |
Satoshi Shinozaki, Hiroyuki Osawa, Yoshimasa Miura, Yoshikazu Hayashi, Hirotsugu Sakamoto, Tomonori Yano, Alan Kawarai Lefor, Hironori Yamamoto. Long-term changes in serum gastrin levels during standard dose vonoprazan therapy. Scandinavian Journal of Gastroenterology 2022; 57(12): 1412 doi: 10.1080/00365521.2022.2097893
|
| 41 |
Daniel Martin Simadibrata, Elvira Lesmana, Ronnie Fass. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta‐analysis of randomized controlled trials. Journal of Gastroenterology and Hepatology 2024; doi: 10.1111/jgh.16486
|
| 42 |
Kang Nyeong Lee, Oh Young Lee, Hoon Jai Chun, Jin Il Kim, Sung Kook Kim, Sang Woo Lee, Kyung Sik Park, Kook Lae Lee, Suck Chei Choi, Jae-Young Jang, Gwang Ha Kim, In-kyung Sung, Moo In Park, Joong Goo Kwon, Nayoung Kim, Jae Jun Kim, Soo Teik Lee, Hyun Soo Kim, Ki Bae Kim, Yong Chan Lee, Myung-Gyu Choi, Joon Seong Lee, Hwoon-Yong Jung, Kwang Jae Lee, Jie-Hyun Kim, Hyunsoo Chung. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World Journal of Gastroenterology 2022; 28(44): 6294-6309 doi: 10.3748/wjg.v28.i44.6294
|
| 43 |
Loren Laine, Kenneth DeVault, Philip Katz, Stefan Mitev, John Lowe, Barbara Hunt, Stuart Spechler. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology 2023; 164(1): 61 doi: 10.1053/j.gastro.2022.09.041
|
| 44 |
Joaquim Prado P MORAES-FILHO, Gerson DOMINGUES, Decio CHINZON. BRAZILIAN CLINICAL GUIDELINE FOR THE THERAPEUTIC MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE (BRAZILIAN FEDERATION OF GASTROENTEROLOGY, FBG). Arquivos de Gastroenterologia 2024; 61 doi: 10.1590/s0004-2803.24612023-154
|
| 45 |
Hyun Kang, Beom Jin Kim, Geunjoo Choi, Jae Gyu Kim. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease. Medicine 2018; 97(39): e12574 doi: 10.1097/MD.0000000000012574
|
| 46 |
Tomohiro Higuchi, Mihoko Yamade, Satoru Takahashi, Satoshi Tamura, Shinya Tani, Takuma Kagami, Takahiro Uotani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Takahisa Furuta. Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel. European Journal of Clinical Pharmacology 2022; 78(6): 955 doi: 10.1007/s00228-022-03313-2
|
| 47 |
Haiying Gong, Di Han, Sen Liu, Chengjiang Liu, Xiaolin Zhu, Diping Chen. Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis. Revista Española de Enfermedades Digestivas 2022; doi: 10.17235/reed.2022.9228/2022
|
| 48 |
Carmelo Scarpignato, Eckhard Leifke, Neila Smith, Darcy J. Mulford, Gezim Lahu, Axel Facius, Colin W. Howden. A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure. The Journal of Clinical Pharmacology 2022; 62(6): 801 doi: 10.1002/jcph.2019
|
| 49 |
Carmelo Scarpignato, Colin W. Howden, Eckhard Leifke, Darcy J. Mulford, Gezim Lahu, Axel Facius, Richard Hunt. A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 2023; 58(1): 16 doi: 10.1111/apt.17510
|
| 50 |
Zhuolin Zhang, Yuwen Bao, Lele Cai, Yajie Gu, Ting Yang, Xin Li. Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China. Clinical Drug Investigation 2022; 42(10): 839 doi: 10.1007/s40261-022-01188-w
|
| 51 |
Nicolas Chapelle, Ines Ben Ghezala, Alan Barkun, Marc Bardou. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opinion on Pharmacotherapy 2021; 22(2): 219 doi: 10.1080/14656566.2020.1817385
|
| 52 |
Yu Kyung Cho, Jae Hak Kim, Hyun‐Soo Kim, Tae‐Oh Kim, Jung‐Hwan Oh, Suck Chei Choi, Jeong Seop Moon, Sang Kil Lee, Sung Woo Jung, Sung Soo Kim, Hye‐Kyung Jung, Sang Pyo Lee, Gab‐Jin Cheon, Moo In Park, Hwoon‐Yong Jung, Kwang Hyun Ko, In Kyung Sung, Si Hyung Lee, Ju Yup Lee, Soo Teik Lee, Poong‐Lyul Rhee, Nayoung Kim, Su Jin Hong, Hyun Jin Kim, Gwang Ha Kim, Kwang Jae Lee, Sung Kook Kim, Woon Geon Shin, Oh Young Lee. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Alimentary Pharmacology & Therapeutics 2023; 57(1): 72 doi: 10.1111/apt.17255
|
| 53 |
Ken Haruma, Yoshikazu Kinoshita, Takashi Yao, Ryoji Kushima, Junichi Akiyama, Nobuo Aoyama, Tatsuhiro Kanoo, Kouji Miyata, Naomi Kusumoto, Naomi Uemura. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02772-w
|